Cwm LLC Acquires 8,313 Shares of Danaher Corporation (NYSE:DHR)

CWM LLC increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 36.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,811 shares of the conglomerate's stock after buying an additional 8,313 shares during the quarter. CWM LLC's holdings in Danaher were worth $6,316,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. FAS Wealth Partners Inc. raised its position in Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares during the last quarter. Horizon Financial Services LLC grew its stake in Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares during the period. Vision Capital Management Inc. acquired a new stake in Danaher during the first quarter worth approximately $461,000. Compass Wealth Management LLC grew its stake in Danaher by 17.4% in the first quarter. Compass Wealth Management LLC now owns 39,764 shares of the conglomerate's stock valued at $8,152,000 after acquiring an additional 5,891 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after acquiring an additional 579,046 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

Shares of NYSE DHR traded down $4.81 during mid-day trading on Friday, hitting $189.98. The company had a trading volume of 4,239,169 shares, compared to its average volume of 3,521,325. The company has a market capitalization of $135.96 billion, a price-to-earnings ratio of 36.89, a P/E/G ratio of 2.73 and a beta of 0.77. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock's 50-day moving average price is $196.13 and its 200-day moving average price is $205.20.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.67%. Danaher's payout ratio is currently 24.85%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on DHR shares. Argus cut their target price on Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. Bank of America cut their target price on Danaher from $265.00 to $230.00 in a research report on Monday, April 14th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Finally, JPMorgan Chase & Co. dropped their price target on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $248.48.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.